Lnd 623

TargetMol
Product Code: TAR-T32829
Supplier: TargetMol
CodeSizePrice
TAR-T32829-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Lnd 623 is an inotropic aminosteroid.
CAS:
90520-42-6
Formula:
C27H47NO6
Molecular Weight:
481.674
Purity:
0.98
SMILES:
[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@@]34N)[C@@H](C)O)[C@@]1(C)CC[C@H](C2)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O

References

1. Jarreau FX, Koenig JJ, Fenard S. A new inotropic aminosteroid: LND 623. Eur Heart J. 1984 Dec;5 Suppl F:309-14. PubMed PMID: 6549446. 2. Weissenburger J, Heckle J, Biour M, Poirier JM, Jarreau FX, Jaillon P, Cheymol G. Comparative hemodynamic study of a new aminosteroid: LND-623 with its 20 alpha-isomer: LND-369, and with digoxin and digoxigenin-rhamnoside in the anesthetized dog. Fundam Clin Pharmacol. 1989;3(1):67-78. PubMed PMID: 2653992. 3. Maixent JM, Berrebi-Bertrand I, Lelievre LG. Inhibition of cardiac (Na+, K+)-ATPase isozymes by LND 623. Biochem Pharmacol. 1991 Dec 11;42 Suppl:S223-4. PubMed PMID: 1662951. 4. Maixent JM, Leli?vre L, Berrebi-Bertrand I. Mechanism underlying the strong positive inotropic effects of LND-623: specific inhibition of Na, K-ATPase isoforms and exclusion of cellular sites of contractile control. Cardiovasc Drugs Ther. 1998 Dec;12(6):585-94. PubMed PMID: 10410828.